In Vivo Therapeutics Core

体内治疗核心

• 批准号: 10247608
• 负责人: Karen Elizabeth Pollok
• 金额: $ 10.28万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-22 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10247608
• 关键词: Adult; Animal Model; Animals; Autopsy; Breeding; Cancer Center; Cancer Center Support Grant; Catchment Area; Cell Therapy; Common Core; Consultations; Core Facility; Data Analyses; Development; Dose; Drug Kinetics; Education; Equipment; Event; Experimental Designs; Financial Support; Future; Gender; Generations; Hematopoietic Stem Cell Transplantation; Human Resources; Hypoxia; Image; In Vitro; Indiana; Individual; Infrastructure; Investigation; Liquid substance; Malignant Neoplasms; Methodology; Monitor; Mouse Strains; Mus; NCI Center for Cancer Research; Peer Review; Pharmacodynamics; Pharmacology; Procedures; Productivity; Radiation; Research; Research Activity; Research Personnel; Resource Sharing; Resources; Route; Sampling; Scientist; Services; Site; Solid Neoplasm; Structure; Students; Surveys; Technology; Testing; Therapeutic; Time; Toxicity Tests; Training; Universities; University resources; Validation; Vendor; Work; Xenograft Model; animal facility; anticancer research; base; cancer biomarkers; cancer therapy; cost effective; cost effectiveness; data hub; education resources; efficacy testing; experimental study; imaging system; improved; in vivo; innovation; investigator-initiated trial; irradiation; live cell imaging; member; mouse model; new therapeutic target; next generation; novel; novel therapeutics; patient derived xenograft model; pediatric patients; pre-clinical; preclinical toxicity; student training

ABSTRACT, In Vivo Therapeutics Core (IVTC) The In Vivo Therapeutics Core (IVTC) is a multi-faceted shared resource facility of the Indiana University Melvin and Bren Simon Cancer Center (IUSCC) that was established to facilitate the discovery and testing of novel pharmacological & cellular therapies. The IVTC is divided into five hubs of research expertise: state-of-the-art equipment for cancer research, breeding of specialized mouse strains, preclinical toxicity and efficacy testing in xenograft models, patient-derived xenografts, and hematopoietic stem-cell transplant studies. Importantly, the IVTC is structured in a way to provide the necessary infrastructure, oversight, and expertise required to successfully meet the needs of the IUSCC investigators. Given the heavy reliance of IUSCC investigators on services provided by IVTC, there is strong rationale to support this centralized shared resource that will facilitate the discovery of new therapies for cancers prominent in the catchment area of Indiana. In the past year, 67% of IVTC users were peer-reviewed Cancer Center members and accounted for 94% of the services invoiced. For the majority of IUSCC members, utilization of mouse models is an essential component of their ongoing research activities focused on development of novel therapies for liquid and solid tumors. To support the needs of the membership, the Aims of the IVTC are: (1) to maintain on-site breeding colonies of mice and establish patient-derived xenografts essential for the exploration, testing, and refinement of novel cancer therapeutics; (2) to provide specialized core services and technology applicable to in vivo studies; and (3) to serve as a consultation and educational resource for IUSCC investigators and trainees. Specifically, the IVTC manages the Radiation facility and will perform irradiation services needed for in vitro and in vivo experiments, including hematopoietic stem-cell transplantations. The IVTC will coordinate all aspects of procedures and provide assistance with experimental design, regulatory requirements, methodology, and data interpretation for each research hub. Shared equipment maintained by the IVTC provides investigators with access to a recently acquired IncuCyteZOOM Live-Cell Imaging System and a hypoxia workstation which are both available for direct use or in partnership with technical staff in the IVTC. In addition, the IVTC will work with IUSCC research teams to coordinate timely delivery of mice and samples to other Core facilities within the IUSCC and the IUSM. As a centralized facility, the IVTC will provide IUSCC investigators advanced resources for analytical and investigational studies essential for the preclinical validation of novel drug targets and biomarkers of cancer so that innovative investigator-initiated trials can be successfully developed.

摘要，体内治疗核心（IVTC） 体内治疗核心（IVTC）是印第安纳州大学梅尔文分校的一个多方面的共享资源设施。 和布伦西蒙癌症中心（IUSCC），成立以促进发现和测试新的 药理学和细胞疗法。IVTC分为五个研究专业中心： 用于癌症研究的设备，专门的小鼠品系的培育，临床前毒性和有效性测试， 异种移植物模型、患者来源的异种移植物和造血干细胞移植研究。重要的是 IVTC的结构是为了提供必要的基础设施，监督和专业知识， 成功地满足了IUSCC研究人员的需求。鉴于IUSCC调查人员严重依赖 由于IVTC提供的服务，有充分的理由支持这种集中共享资源， 在印第安纳州的集水区发现了治疗癌症的新疗法。去年，67%的 IVTC用户是同行评审的癌症中心成员，占服务发票的94%。为 大多数IUSCC成员认为，小鼠模型的利用是他们正在进行的研究的重要组成部分 活动重点是开发液体和固体肿瘤的新疗法。为了满足 委员会的宗旨是：（1）维持本地繁殖鼠群， 患者来源的异种移植物对于探索、测试和改进新型癌症至关重要 （2）提供适用于体内研究的专业核心服务和技术;以及 (3)作为IUSCC调查人员和学员的咨询和教育资源。具体地说， IVTC管理辐射设施，并将执行体外和体内所需的辐射服务 实验，包括造血干细胞移植。IVTC将协调各方面的工作， 程序，并提供实验设计，法规要求，方法和数据方面的帮助 每个研究中心的口译。由IVTC维护的共享设备为研究人员提供 访问最近获得的IncuCyteZOOM活细胞成像系统和缺氧工作站， 两者均可直接使用或与IVTC的技术人员合作使用。此外，IVTC将与 IUSCC研究团队协调及时向IUSCC内的其他核心设施交付小鼠和样本 和IUSM。作为一个集中的机构，IVTC将为IUSCC研究人员提供先进的资源， 分析和调查研究对于新药靶点和生物标志物的临床前验证至关重要 因此，创新的药物启动试验可以成功开发。